DGIdb - TAK-733 Drug Record

TAK-733 chembl:CHEMBL1615025 Antineoplastic

Alternate Names:

TAK 733
TAK-733
TAK733

Drug Info:

Pharmaceutical Developer	Millennium Pharmaceuticals
Source Reported Drug Name(s)	TAK-733
Drug Class	MEK Inhibitor
Notes	allosteric inhibitor
Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Lieu et al., 2015, Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts., Oncotarget
Acquaviva et al., 2014, Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib., Mol. Cancer Ther.
Dahlman et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov
von Euw et al., 2012, Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines., Mol. Cancer

TAK-733 GNA11

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB
TAK-733 GNAQ

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB
TAK-733 MAP2K1

Interaction Score: 0.62

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons
TAK-733 MAP2K2

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions
TAK-733 NRAS

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26439693

Sources:
JAX-CKB
TAK-733 BRAF

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26439693 24398428 22798288

Sources:
JAX-CKB
TAK-733 KRAS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
26439693

Sources:
JAX-CKB
TAK-733 PIK3CA

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Preclinical - Pdx & cell culture

PMIDs:
26439693

Sources:
JAX-CKB

CancerCommons: TAK-733
- Version: 25-July-2013
Alternate Names:

TAK-733 PubChem Drug Name

24963252 PubChem Drug ID

TAK-733 Drug Trade Name

Drug Info:

Drug Class MEK Inhibitor

Source Reported Drug Name(s) TAK-733

Pharmaceutical Developer Millennium Pharmaceuticals

Publications:
MyCancerGenome: TAK-733
- Version: 20-Jun-2017
Alternate Names:

TAK-733 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Notes allosteric inhibitor

Publications:
TTD: TAK-733
- Version: 2020.06.01
Alternate Names:

D0I3RD TTD Drug ID

Drug Info:

Publications:

Akinleye A et al., 2013, MEK and the inhibitors: from bench to bedside., J Hematol Oncol

JAX-CKB: TAK-733

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

von Euw et al., 2012, Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines., Mol. Cancer

Lieu et al., 2015, Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts., Oncotarget

Dahlman et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov

ChemblDrugs: chembl:CHEMBL1615025
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1615025
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: TAK-733
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	uveal melanoma
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Direct Interaction	yes
Mechanism of Interaction	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
Reported Cancer Type	Melanoma

Indication/Tumor Type	colorectal cancer
Response Type	predicted – sensitive
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	cholangiocarcinoma
Response Type	sensitive
Approval Status	Preclinical - Pdx

TAK-733	PubChem Drug Name
24963252	PubChem Drug ID
TAK-733	Drug Trade Name

allosteric modulator
inhibitor (inhibitory)

TAK-733 Drug Record

TAK-733 chembl:CHEMBL1615025 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22515704

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22515704

Sources: JAX-CKB

Interaction Types & Directionality: allosteric modulator inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Reported Cancer Type Melanoma

PMIDs: None found

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type predicted – sensitive Approval Status Preclinical - Cell culture

PMIDs: 26439693

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Phase I

PMIDs: 26439693 24398428 22798288

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type cholangiocarcinoma Response Type sensitive Approval Status Preclinical - Pdx

PMIDs: 26439693

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type predicted – sensitive Approval Status Preclinical - Pdx & cell culture

PMIDs: 26439693

Sources: JAX-CKB

CancerCommons: TAK-733

Alternate Names: TAK-733 PubChem Drug Name 24963252 PubChem Drug ID TAK-733 Drug Trade Name

Drug Info: Drug Class MEK Inhibitor Source Reported Drug Name(s) TAK-733 Pharmaceutical Developer Millennium Pharmaceuticals

Publications:

MyCancerGenome: TAK-733

Alternate Names: TAK-733 Development Name

Drug Info: Drug Class Kinase Inhibitors Notes allosteric inhibitor

Publications:

TTD: TAK-733

Alternate Names: D0I3RD TTD Drug ID

Drug Info:

Publications: Akinleye A et al., 2013, MEK and the inhibitors: from bench to bedside., J Hematol Oncol

JAX-CKB: TAK-733

Alternate Names:

Drug Info:

ChemblDrugs: chembl:CHEMBL1615025

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1615025

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: TAK-733

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26439693

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26439693 24398428 22798288

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
26439693

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Preclinical - Pdx & cell culture

PMIDs:
26439693

Sources:
JAX-CKB

Alternate Names:

TAK-733 PubChem Drug Name

24963252 PubChem Drug ID

TAK-733 Drug Trade Name

Drug Info:

Drug Class MEK Inhibitor

Source Reported Drug Name(s) TAK-733

Pharmaceutical Developer Millennium Pharmaceuticals

Alternate Names:

TAK-733 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Notes allosteric inhibitor

Alternate Names:

D0I3RD TTD Drug ID

Publications:

Akinleye A et al., 2013, MEK and the inhibitors: from bench to bedside., J Hematol Oncol